A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight

• Status: Recruiting
• Trial end date: 2025-10-21
• Target enrollment: 0
• Participant gender: All

Summary

This study will look at how well CagriSema compared to Tirzepatide helps people lower their body weight. CagriSema is a new investigational medicine developed by Novo Nordisk that combines Cagrilintide and Semaglutide. CagriSema is not yet being prescribed by doctors. Participant will get injections once a week throughout the treatment period. Participant will inject the study medicine under the skin with a pen injector in the thigh, stomach, or upper arm. After a first low dose, the study medicine will be gradually increased until reaching the planned dose (2.4 mg CagriSema or 15 mg Tirzepatide). The study will last for about one and a half year for each participant.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Semaglutide; Tirzepatide

Criteria

Inclusion Criteria:

• Male or female

• Age 18 years or above at the time of signing the informed consent

• Body mass index (BMI) of ≥ 30.0 kilogram per square meter (kg/m^2)

Exclusion Criteria:

• Glycated haemoglobin (HbA1c) ≥ 6.5 % (48 millimoles per mole [mmol/mol]) as measured by the central laboratory at screening

• History of type 1 or type 2 diabetes mellitus